world-biomarkers-pharma-biotech-2017-posters

30 / 61

Notes:
Volume10, Issue 12 (Suppl) J Proteomics Bioinform, an open access journal
ISSN: 0974-276X
Page 86
conferenceseries.com
World Biomarkers & Pharma Biotech 2017
December 07-09, 2017
December 07-09, 2017 | Madrid, Spain
&
20th International Conference on
PHARMACEUTICAL BIOTECHNOLOGY
9th WORLD BIOMARKERS CONGRESS
JOINT EVENT ON
UMELISA EGF®: The companion kit for CIMAvax-EGF® vaccine
Idania González Pérez
Center of Molecular Immunology, Cuba
Background: CIMAvax-EGF® is a Cuban therapeutic vaccine approved for treatment of advanced non-small cell lung cáncer
(NSCLC). By inducing antibodies vs. epidermal growth factor (EGF), it prevents binding of endogenous EGF to its receptor,
thereby reducing tumor size and/or its progression. Phase II and III clinical trials carried out in Cuban patients revealed the
pre-treatment predictive value of serum EGF concentrations ([sEGF]) for CIMAvax-EGF® efficacy. Therefore, it makes sense
to identify the subset of patients which will be really benefitted with the use of the vaccine, through its stratification by [sEGF]
(personalized medicine). The aim of this work was to develop and validate the UMELISA EGF® kit, the future companion
diagnostic kit of CIMAvax-EGF® vaccine.
Methods: The ultra micro analytical system technology (Immunoassay Center, Cuba) was used. The system includes the plate
washer and instrumentation for automatic reading, quantification, validation and interpretation of results.
Results: A simple sandwich-type ultramicroELISA assay UMELISA EGF®, based on the advantages of high affinity reaction
between streptavidin and biotin, was developed for the measurement of [sEGF]. The best performance was achieved with: plates
coated with mAb CBEGF-1 at 6 μg/mL, biotinylated mAb CBEGF-2 at 0.5 μg/mL, incubation time for sandwich formation of
18-20 hours at 37 °C and sample volumes of 30 uL.
Conclusions: The UMELISA EGF® kit exhibited similar characteristics to other commercially available assays, in terms of
precision, accuracy and dynamic range. Regression analysis showed a good correlation with the commercially available
Human EGF Immunoassay Quantikine® ELISA kit (n=130, Pearson r=0.92, p<0.01) (R&D Systems, USA).
Biography
Idania González Pérez has completed her BSc in Physics from the Faculty of Physics, Moscow State University, Russia (1985-1990) and Master of Science in
Physics and Mathematics from Faculty of Physics, Moscow State University, Russia. She is now involved in a PhD program at the University School of Medicine in
Havana. She is a Senior Researcher at the Center for Molecular Immunology in Havana, Systems Biology Department, Biomarkers Group. She has published more
than 15 papers in reputed journals and has been serving as a Reviewer in Medical Science Monitor, Journal of Hospital and Clinical Pharmacy and International
Blood Research & Reviews.
Idania González Pérez, J Proteomics Bioinform 2017, 10:12(Suppl)
DOI: 10.4172/0974-276X-C1-110